1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) via NIH SBIR Program. This funding opportunity supports small business concerns (SBCs) to develop technologies for commercialization that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder.
This includes digital services, software as a service, digital applications, and mobile health applications that can address social determinants of health and improve SUD outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small business concerns (SBCs) developing technologies for commercialization. Small businesses must be U.S.-based and meet SBIR/STTR eligibility requirements. Confirm the full requirements in the official notice before applying.
The current listing shows $400,000 (Phase I); $3,000,000 (Phase II). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) is funded by National Institute on Drug Abuse (NIDA) via NIH SBIR Program. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleNIH's FY2026 omnibus adds a Phase IIB Strategic Breakthrough Award up to $30M — but it requires a 100% outside match. Here's who it's for and how to plan.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read article